New anti-epileptic drugs: overcoming the limits of randomised controlled trials

Area of Science:

• * Neurology
• * Clinical Trials Methodology

Background:

• * Randomized controlled trials (RCTs) are essential for evaluating new anti-epileptic drugs (AEDs) for focal epilepsy.
• * Current RCT designs often have limitations, particularly placebo-controlled trials, hindering direct comparisons between novel AEDs.

Purpose of the Study:

• * To critically analyze the designs of RCTs for new AEDs in focal epilepsy.
• * To discuss the limitations of existing trial designs, focusing on placebo-controlled studies.
• * To propose strategies for overcoming these design limitations.

Main Methods:

• * Review and commentary on existing RCT designs for AEDs in focal epilepsy.
• * Discussion of alternative methodologies such as multiple-treatment meta-analysis and historical control trials.
• * Emphasis on the need for direct head-to-head comparisons.

Main Results:

• * Few head-to-head comparison trials currently exist between new AEDs.
• * Multiple-treatment meta-analysis offers a way to rank AED efficacy and inform clinical decisions.
• * Historical design trials may offer advantages by ensuring all participants receive active treatment.

Conclusions:

• * While meta-analysis and historical designs can mitigate limitations, they are not substitutes for direct comparison RCTs.
• * Properly conducted direct-comparison RCTs remain the gold standard for informing clinical decisions in focal epilepsy treatment.
• * Addressing design limitations is key to optimizing evidence generation for new AEDs.